$UTHR
UNITED THERAPEUTICS Corp

2020 Q4 Form 10-Q Financial Statement

#000108255420000017 Filed on October 28, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $384.9M $380.1M $401.5M
YoY Change 23.72% -5.33% -2.71%
Cost Of Revenue $34.80M $24.00M $33.00M
YoY Change 20.83% -27.27% -36.42%
Gross Profit $350.1M $356.1M $368.5M
YoY Change 24.02% -3.36% 2.13%
Gross Profit Margin 90.96% 93.69% 91.78%
Selling, General & Admin $158.7M $66.30M $99.40M
YoY Change 50.86% -33.3% -9.72%
% of Gross Profit 45.33% 18.62% 26.97%
Research & Development $126.1M $68.70M $85.70M
YoY Change 11.0% -19.84% -15.23%
% of Gross Profit 36.02% 19.29% 23.26%
Depreciation & Amortization $13.10M $11.80M $12.70M
YoY Change 4.8% -7.09% 35.11%
% of Gross Profit 3.74% 3.31% 3.45%
Operating Expenses $284.8M $68.70M $85.70M
YoY Change 30.16% -19.84% -15.23%
Operating Profit $65.30M $221.1M $183.4M
YoY Change 2.83% 20.56% 22.59%
Interest Expense -$53.40M $4.900M $11.70M
YoY Change -1670.59% -58.12% 185.37%
% of Operating Profit -81.78% 2.22% 6.38%
Other Income/Expense, Net $102.5M -$2.100M -$16.50M
YoY Change 7221.43% -87.27% 73.68%
Pretax Income $114.4M $219.0M $166.9M
YoY Change 67.5% 31.22% 19.13%
Income Tax $15.60M $47.80M $34.50M
% Of Pretax Income 13.64% 21.83% 20.67%
Net Earnings $98.80M $171.2M $132.4M
YoY Change 87.83% 29.31% 24.32%
Net Earnings / Revenue 25.67% 45.04% 32.98%
Basic Earnings Per Share $3.86 $3.02
Diluted Earnings Per Share $2.186M $3.84 $3.01
COMMON SHARES
Basic Shares Outstanding 44.44M shares 44.40M shares 43.90M shares
Diluted Shares Outstanding 44.60M shares 44.00M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.835B $1.581B $1.570B
YoY Change 23.49% 0.67% 26.86%
Cash & Equivalents $738.7M $670.2M $719.7M
Short-Term Investments $1.096B $910.3M $850.3M
Other Short-Term Assets $88.30M $47.50M $85.70M
YoY Change -34.01% -44.57% 56.1%
Inventory $86.50M $87.90M $94.10M
Prepaid Expenses
Receivables $157.4M $152.3M $183.6M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.167B $1.868B $1.933B
YoY Change 16.23% -3.37% 20.18%
LONG-TERM ASSETS
Property, Plant & Equipment $731.6M $736.4M $678.3M
YoY Change -0.93% 8.57% 1.97%
Goodwill $28.00M $28.00M $28.00M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $1.150B $1.228B $730.4M
YoY Change 49.79% 68.06% 22.57%
Other Assets $169.9M $165.4M $231.0M
YoY Change 9.9% -28.4% -38.33%
Total Long-Term Assets $2.448B $2.543B $2.066B
YoY Change 19.47% 23.08% 14.57%
TOTAL ASSETS
Total Short-Term Assets $2.167B $1.868B $1.933B
Total Long-Term Assets $2.448B $2.543B $2.066B
Total Assets $4.615B $4.411B $4.000B
YoY Change 17.93% 10.29% 17.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.100M $177.1M $161.1M
YoY Change -58.59% 9.93% -21.34%
Accrued Expenses $182.9M $1.900M
YoY Change 32.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $250.0M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $323.3M $258.9M $469.9M
YoY Change -30.17% -44.9% 26.18%
LONG-TERM LIABILITIES
Long-Term Debt $800.0M $800.0M $750.0M
YoY Change 33.33% 6.67% 200.0%
Other Long-Term Liabilities $96.50M $69.20M $63.90M
YoY Change 37.86% 8.29% -17.76%
Total Long-Term Liabilities $96.50M $69.20M $63.90M
YoY Change 37.86% 8.29% -80.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $323.3M $258.9M $469.9M
Total Long-Term Liabilities $96.50M $69.20M $63.90M
Total Liabilities $1.220B $1.128B $1.284B
YoY Change 7.66% -12.13% 83.37%
SHAREHOLDERS EQUITY
Retained Earnings $3.839B $3.740B $3.273B
YoY Change 15.46% 14.29%
Common Stock $2.149B $2.126B $2.027B
YoY Change 4.92% 4.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.395B $3.283B $2.716B
YoY Change
Total Liabilities & Shareholders Equity $4.615B $4.411B $4.000B
YoY Change 17.93% 10.29% 17.22%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $98.80M $171.2M $132.4M
YoY Change 87.83% 29.31% 24.32%
Depreciation, Depletion And Amortization $13.10M $11.80M $12.70M
YoY Change 4.8% -7.09% 35.11%
Cash From Operating Activities $126.2M $250.9M $185.4M
YoY Change 23.12% 35.33% -21.94%
INVESTING ACTIVITIES
Capital Expenditures -$12.30M -$15.80M -$13.60M
YoY Change -50.2% 16.18% -67.23%
Acquisitions
YoY Change
Other Investing Activities -$51.50M -$255.9M -$285.1M
YoY Change -156.66% -10.24% -1.14%
Cash From Investing Activities -$63.80M -$271.7M -$298.7M
YoY Change -196.37% -9.04% -9.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.100M 5.600M -48.30M
YoY Change -104.07% -111.59% -2112.5%
NET CHANGE
Cash From Operating Activities 126.2M 250.9M 185.4M
Cash From Investing Activities -63.80M -271.7M -298.7M
Cash From Financing Activities 6.100M 5.600M -48.30M
Net Change In Cash 68.50M -15.20M -161.6M
YoY Change 266.31% -90.59% 79.56%
FREE CASH FLOW
Cash From Operating Activities $126.2M $250.9M $185.4M
Capital Expenditures -$12.30M -$15.80M -$13.60M
Free Cash Flow $138.5M $266.7M $199.0M
YoY Change 8.88% 34.02% -28.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001082554
dei Amendment Flag
AmendmentFlag
false
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-26301
dei Entity Registrant Name
EntityRegistrantName
United Therapeutics Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-1984749
dei Entity Address Address Line1
EntityAddressAddressLine1
1040 Spring Street,
dei Entity Address City Or Town
EntityAddressCityOrTown
Silver Spring,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei City Area Code
CityAreaCode
(301)
dei Local Phone Number
LocalPhoneNumber
608-9292
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20910
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
UTHR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44440534 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
670200000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
738400000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
910300000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
747500000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
152300000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
151400000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
87900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
93400000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
47500000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
133800000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1868200000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1864500000 USD
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1227500000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
767500000 USD
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158200000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158300000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
736400000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
738500000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
255500000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
230000000.0 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
165400000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154600000 USD
CY2020Q3 us-gaap Assets
Assets
4411200000 USD
CY2019Q4 us-gaap Assets
Assets
3913400000 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
177100000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
148400000 USD
CY2020Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 USD
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
250000000.0 USD
CY2020Q3 uthr Share Tracking Award Plans
ShareTrackingAwardPlans
32200000 USD
CY2019Q4 uthr Share Tracking Award Plans
ShareTrackingAwardPlans
25000000.0 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
49600000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39600000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
258900000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
463000000.0 USD
CY2020Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
800000000.0 USD
CY2019Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
600000000.0 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
69200000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70000000.0 USD
CY2020Q3 us-gaap Liabilities
Liabilities
1128100000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
1133000000.0 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71059151 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70503775 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44439935 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43884559 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
700000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
700000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2125700000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2047900000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4500000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14200000 USD
CY2020Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26619216 shares
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26619216 shares
CY2020Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2579200000 USD
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2579200000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3740400000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3325200000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3283100000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2780400000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4411200000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3913400000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
401500000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1137700000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000000.0 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33000000.0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
73300000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
88800000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68700000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85700000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231600000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1069000000.0 USD
CY2020Q3 uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
66300000 USD
CY2019Q3 uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
99400000 USD
uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
265200000 USD
uthr Selling General And Administrative Expense And Adjustments
SellingGeneralAndAdministrativeExpenseAndAdjustments
231000000.0 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
159000000.0 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
218100000 USD
us-gaap Costs And Expenses
CostsAndExpenses
570100000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1388800000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221100000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
183400000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
528300000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-251100000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6400000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12100000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
23600000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
32700000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4900000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
11700000 USD
us-gaap Interest Expense
InterestExpense
18700000 USD
us-gaap Interest Expense
InterestExpense
34200000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16900000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
400000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19300000 USD
CY2020Q3 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
3500000 USD
CY2019Q3 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
0 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
9100000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
0 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2100000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16500000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3800000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17800000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
219000000.0 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
166900000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
524500000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-233300000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47800000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34500000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108500000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-76200000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
132400000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-157100000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.84
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44400000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44100000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43800000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44600000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43800000 shares
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
132400000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-157100000 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
0 USD
CY2019Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
200000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-600000 USD
CY2020Q3 uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
300000 USD
CY2019Q3 uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
-100000 USD
uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
900000 USD
uthr Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax
OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax
-1600000 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-300000 USD
CY2019Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
100000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-1100000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
2200000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2700000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000.0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8600000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000000.0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2400000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
900000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9700000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3800000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
168800000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
133300000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
425700000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-153300000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3093700000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2700000 USD
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-300000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2200000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
100000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3500000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15000000.0 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3283100000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2558400000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
132400000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000000.0 USD
CY2019Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
100000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1900000 USD
CY2019Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
200000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22500000 USD
CY2019Q3 uthr Deconsolidation Gain Loss Of Variable Interest Entity
DeconsolidationGainLossOfVariableInterestEntity
-100000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
2715800000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2780400000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8600000 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-1100000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4700000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3600000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25900000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50800000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3283100000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2788600000 USD
us-gaap Net Income Loss
NetIncomeLoss
-157100000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000000.0 USD
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
2200000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4100000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2100000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9900000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63000000.0 USD
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
10800000 USD
uthr Deconsolidation Gain Loss Of Variable Interest Entity
DeconsolidationGainLossOfVariableInterestEntity
-100000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
2715800000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-157100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36800000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33400000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
70100000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
15900000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
9100000 USD
uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
0 USD
uthr Variable Interest Entity Deconsolidation
VariableInterestEntityDeconsolidation
0 USD
uthr Variable Interest Entity Deconsolidation
VariableInterestEntityDeconsolidation
2000000.0 USD
uthr Impairment Of Intangible Assets
ImpairmentOfIntangibleAssets
0 USD
uthr Impairment Of Intangible Assets
ImpairmentOfIntangibleAssets
8800000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5400000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
8400000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6800000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
27900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7800000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11100000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10500000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
27900000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4900000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-60800000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
190400000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
629500000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-309100000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000000.0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000000.0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2400000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
uthr Decrease In Cash Due To Deconsolidation Of Variable Interest Entity
DecreaseInCashDueToDeconsolidationOfVariableInterestEntity
0 USD
uthr Decrease In Cash Due To Deconsolidation Of Variable Interest Entity
DecreaseInCashDueToDeconsolidationOfVariableInterestEntity
12500000 USD
uthr Advance Payment Related To Property Plant And Equipment
AdvancePaymentRelatedToPropertyPlantAndEquipment
0 USD
uthr Advance Payment Related To Property Plant And Equipment
AdvancePaymentRelatedToPropertyPlantAndEquipment
5600000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
39700000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1698800000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
974700000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1041400000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
618500000 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
27300000 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
0 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
0 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
8000000.0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-674700000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-401600000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
800000000.0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
50000000.0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
50000000.0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
700000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25900000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9900000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4700000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4100000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3600000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2100000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23000000.0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
761200000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68200000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50500000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
738400000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
669200000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
670200000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
719700000 USD
us-gaap Interest Paid Net
InterestPaidNet
16600000 USD
us-gaap Interest Paid Net
InterestPaidNet
31700000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
62300000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
94400000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4400000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3900000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business Description<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (FDA) to market the following therapies: Remodulin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (treprostinil) Injection (Remodulin), Tyvaso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (Tyvaso), Orenitram</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (Orenitram), Unituxin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (Unituxin), and Adcirca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (Adcirca). Our only significant revenues outside the United States are derived from sales of Remodulin in Europe. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms “we”, “us”, “our”, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles (GAAP) for complete financial statements. These consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 26, 2020. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our management’s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of September 30, 2020 and December 31, 2019, our statements of operations, comprehensive income, and stockholders’ equity for the three- and nine-month periods ended September 30, 2020 and 2019, and statements of cash flows for the nine-month periods ended September 30, 2020 and 2019. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Adopted During the Period</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13), which introduces new guidance for estimating credit losses on certain types of financial instruments based on expected losses and the timing of the recognition of such losses. <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyMTBjYzRiMGMwZDQyOTVhMjkxYzA0NmVkZmEyZTE1L3NlYzozMjEwY2M0YjBjMGQ0Mjk1YTI5MWMwNDZlZGZhMmUxNV80MC9mcmFnOjE3ZjFjNjFkYTliMzQwM2Q4OGQ1YTdkNzAzYjA5YjA0L3RleHRyZWdpb246MTdmMWM2MWRhOWIzNDAzZDg4ZDVhN2Q3MDNiMDliMDRfMzI5ODUzNDg4OTE0Nw_3971d65a-29ea-434e-9a21-b2760f6c27e1">ASU 2016-13</span> is effective for interim and annual reporting periods beginning after December 15, 2019. We adopted this standard on January 1, 2020 using the modified retrospective method for financial assets measured at amortized cost, including our net investment in a sales-type lease, financing receivables, and trade receivables. Upon adoption of the new standard, we recorded an allowance for credit losses of $1.1 million related to our net investment in a lease using an estimated default rate for the lessee over the lease term. The cumulative-effect adjustment resulted in a decrease to retained earnings of $0.8 million, which is net of a tax benefit. During the first quarter of 2020, we recognized an impairment charge of $1.5 million on a note receivable due to the expected loss from future payments as a result of economic uncertainty arising from the negative effects which the COVID-19 pandemic has had on the global economy and financial markets. We did not recognize any further impairment of this note receivable during the second and third quarters of 2020. We recorded this impairment charge within “other (expense) income, net” on our consolidated statements of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04), which simplifies how an entity is required to test goodwill for impairment. ASU 2017-04 requires that a goodwill impairment be measured by the amount by which a reporting unit’s carrying value exceeds its fair value, with the amount of impairment not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for goodwill impairment tests in fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, and must be adopted on a prospective basis. We adopted the new standard on January 1, 2020, with no material impact on our financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-13), which eliminates, adds, and modifies certain disclosure requirements for fair value measurements. ASU 2018-13 is effective for interim and annual reporting periods beginning after December 15, 2019. We adopted the new standard on January 1, 2020, with no material impact on our financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Retirement Benefits-Defined Benefit Plans-General (Topic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2018-14). The standard modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. ASU 2018-14 is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2019-12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which simplifies the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, Income Taxes, and also improves consistency of application by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2020-01), which addresses the accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2020-04), which provides optional expedients and exceptions to lessen the burden of accounting for contract modifications and hedging relationships that reference LIBOR or other reference rates that could be discontinued due to reference rate reform. ASU 2020-04 is effective immediately and may be applied through December 31, 2022. We are currently evaluating the impact of the expedients and exceptions of this new standard on our accounting for our credit agreement, which references LIBOR.</span></div>
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2104500000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15700000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
200000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2120000000.0 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2120000000.0 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1447600000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4600000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
200000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1452000000.0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1452000000.0 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
889700000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
892500000 USD
CY2020Q3 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughThreeAmortizedCostBasis
1214800000 USD
CY2020Q3 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Year Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughYearThreeFairValue
1227500000 USD
CY2020Q3 uthr Contractual Maturities Of Available For Sale Debt Securities Amortized Cost Basis
ContractualMaturitiesOfAvailableForSaleDebtSecuritiesAmortizedCostBasis
2104500000 USD
CY2020Q3 uthr Contractual Maturities Of Available For Sale Securities Debt Securities
ContractualMaturitiesOfAvailableForSaleSecuritiesDebtSecurities
2120000000.0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
683300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
684500000 USD
CY2019Q4 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughThreeAmortizedCostBasis
764300000 USD
CY2019Q4 uthr Available For Sale Securities Debt Maturities Rolling Year One Through Year Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughYearThreeFairValue
767500000 USD
CY2019Q4 uthr Contractual Maturities Of Available For Sale Debt Securities Amortized Cost Basis
ContractualMaturitiesOfAvailableForSaleDebtSecuritiesAmortizedCostBasis
1447600000 USD
CY2019Q4 uthr Contractual Maturities Of Available For Sale Securities Debt Securities
ContractualMaturitiesOfAvailableForSaleSecuritiesDebtSecurities
1452000000.0 USD
us-gaap Proceeds From Sale Of Trading Securities Heldforinvestment
ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
27300000 USD
CY2020Q1 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
5600000 USD
CY2020Q3 uthr Impairment Of Investments In Privately Held Companies
ImpairmentOfInvestmentsInPrivatelyHeldCompanies
3500000 USD
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
19900000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
21100000 USD
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
30000000.0 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
29100000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
38000000.0 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
43200000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
87900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
93400000 USD
CY2020Q3 us-gaap Goodwill Gross
GoodwillGross
28000000.0 USD
CY2020Q3 us-gaap Goodwill
Goodwill
28000000.0 USD
CY2019Q4 us-gaap Goodwill Gross
GoodwillGross
28000000.0 USD
CY2019Q4 us-gaap Goodwill
Goodwill
28000000.0 USD
CY2020Q3 uthr Goodwill And Other Intangibles Assets Gross
GoodwillAndOtherIntangiblesAssetsGross
163600000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5400000 USD
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158200000 USD
CY2019Q4 uthr Goodwill And Other Intangibles Assets Gross
GoodwillAndOtherIntangiblesAssetsGross
163600000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5300000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
158300000 USD
CY2020Q3 uthr Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2 plan
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-12500000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23900000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70100000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15900000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
171200000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
132400000 USD
us-gaap Net Income Loss
NetIncomeLoss
416000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-157100000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44400000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44100000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43800000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
200000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
100000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
300000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44600000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43800000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.84
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7500000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000.0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7100000 shares
uthr Number Of Distributors
NumberOfDistributors
2 distributor
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.33
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019 uthr Interest Expense Related To Uncertain Tax Positions
InterestExpenseRelatedToUncertainTaxPositions
0 USD
uthr Interest Expense Related To Uncertain Tax Positions
InterestExpenseRelatedToUncertainTaxPositions
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24000000.0 USD
CY2020Q3 uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
356100000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
401500000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33000000.0 USD
uthr Number Of Distributors
NumberOfDistributors
2 distributor
CY2019Q3 uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
368500000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
73300000 USD
uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
1025100000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1137700000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
88800000 USD
uthr Gross Profit Excluding Other Revenue
GrossProfitExcludingOtherRevenue
1048900000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380100000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
401500000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1098400000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1137700000 USD

Files In Submission

Name View Source Status
0001082554-20-000017-index-headers.html Edgar Link pending
0001082554-20-000017-index.html Edgar Link pending
0001082554-20-000017.txt Edgar Link pending
0001082554-20-000017-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
uthr-20200930.htm Edgar Link pending
uthr-20200930.xsd Edgar Link pending
uthr-20200930_cal.xml Edgar Link unprocessable
uthr-20200930_def.xml Edgar Link unprocessable
uthr-20200930_htm.xml Edgar Link completed
uthr-20200930_lab.xml Edgar Link unprocessable
uthr-20200930_pre.xml Edgar Link unprocessable
uthrex31109302020.htm Edgar Link pending
uthrex31209302020.htm Edgar Link pending
uthrex32109302020.htm Edgar Link pending
uthrex32209302020.htm Edgar Link pending